ClinicalTrials.gg
Active, not recruitingNCT06150014Updated Nov 14, 2024

A Clinical Study of TQA3605 Tablets Monotherapy or in Combination With Nucleoside (Acid) Analogues in Treatment Naive and Treated Patients With Chronic Hepatitis B

A Phase 1/2 interventional study of Placebo and TQA3605 tablets in Chronic Hepatitis b, sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd.. Active, not recruiting at 3 sites in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2024-11-14.

Sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (part of Sino Biopharmaceutical Limited) · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Dec 2025, 11 months ago, but the record still lists the study as active, not recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
88
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 13 studies in Hepatitis B, Chronic by Sino Biopharmaceutical Limited — 4 open to participants now, 6 under way, 1 of them phase 3. Hepatitis B, Chronic · Sino Biopharmaceutical Limited.

Enrollment
9th of 13
88 · median 116
Started
2023
with 1 other
Phase 1/2
2 of 13
1 open now
Registered
7th of 13
by date

Among the 13 studies in Hepatitis B, Chronic by Sino Biopharmaceutical Limited, this one is the 9th largest by enrollment, is one of 2 that started in 2023, is one of 2 in phase 1/2, and was the 7th registered.

Hepatitis B, Chronic

896 studies on the registry are indexed under Hepatitis B, Chronic; 153 are open to participants now.

Browse Hepatitis B, Chronic studies →

Open to participants now

4 of the 13 studies in Hepatitis B, Chronic by Sino Biopharmaceutical Limited are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 97 Hepatitis B, Chronic studies recruiting now, 33 (34%) set no upper age limit and 59 (61%) stop at 75 or younger; 11 take children under 18; 13 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Hepatitis B, Chronic by Sino Biopharmaceutical Limited, or all of them as a file.
02

Study summary

A randomized, double-blind Phase Ib/IIa multicenter trial design was used. All eligible subjects received TQA3605 tablets/placebo plus nucleoside (acid) analogues. A total of 88 subjects were required

03

Conditions studied

  • Chronic Hepatitis b

Browse trials for

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects voluntarily participate in this study and sign ;
  • Male and female, ≥18 years old and ≤70 years old (subject to the date of signing the informed consent);
  • Patients diagnosed with chronic (CHB) who have been serum HBsAg positive for more than 6 months and HBeAg positive or negative ;
  • The liver fibrosis ultrasound transient imaging elastic technology (Fibroscan/FibroTouch) showed that the liver hardness (LSM) was less than 12.4 Kpa;
  • Patients with chronic hepatitis B after treatment;
  • Treatment-naïve patients of chronic hepatitis B patients;

Exclusion criteria

Exclusion Criteria:

  • Complicated with other infected disease such as hepatitis A virus (HAV), virus (HCV), Hepatitis D virus (HDV), hepatitis E virus (HEV), (HIV), syphilis (syphilis antibody positive and need treatment determined by the investigator);
  • Abdominal ultrasound or other imaging or histology showed suspected cirrhosis or other liver disease before or during screening;
  • Patients have a history of hepatocellular carcinoma (HCC) before or at the time of screening, or may be at risk for HCC;
  • Active disease diagnosed with immunodeficiency or undergoing systemic therapy which was continuing within 2 weeks before first dosing;
  • Currently being treated with nephrotoxic drugs or drugs that alter renal excretion;
  • Abnormal thyroid function;
  • Renal diseases such as chronic kidney disease and renal insufficiency or (CLCr) \<60 ml/min during the screening period;
  • Hematologic and biochemical abnormalities;
  • History of allergy to the drug or its ;
  • Recipients of solid organs or bone marrow transplants;
  • A history of malignant tumors within the past 5 years;
  • Interstitial lung disease, acute lung disease, etc.;
  • Uncontrolled systemic diseases such as high blood pressure and diabetes;
  • Have used any investigational drug or participated in a clinical trial within one month prior to the administration of study drug;
  • Those who received within 28 days before the start of study treatment, inactivated vaccine within 7 days, or planned vaccination during the study period;
  • The investigator determines that there is any medical or psychiatric condition that puts the subject at risk, interferes with participation in the study, or interferes with the interpretation of the study results;
  • Female subjects that were pregnant, lactating or had a positive pregnancy result during the screening period or during the trial; Male and female patients with who were unwilling to use effective methods during the study period;
  • Subjects who have any medical condition that may affect the absorption of oral drugs;
  • Within 12 weeks prior to screening, treated chronic patients who had stopped taking nucleoside (acid) analogues for more than 14 consecutive days;
  • Those considered unsuitable for enrollment by the investigators.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
88 participants (actual)

Study arms

  • Placebo comparator
    Placebo +Nucleoside (acid) analogs (NAs) combination therapy 24 weeks

    Placebo and Nucleoside (acid) analogues, taken orally once daily, continue for 24 weeks.

    Drug: Placebo · Drug: Entecavir dispersible tablets · Drug: Tenofovir disoproxil fumarate tablet · Drug: Tenofovir alafenamide fumarate tablet

  • Active comparator
    50 mg of TQA3605 tablets +NAs combination therapy 24 weeks

    50 mg of TQA3605 tablets and Nucleoside (acid) analogues, taken orally once daily, continue for 24 weeks.

    Drug: TQA3605 tablets · Drug: Entecavir dispersible tablets · Drug: Tenofovir disoproxil fumarate tablet · Drug: Tenofovir alafenamide fumarate tablet

  • Active comparator
    100 mg of TQA3605 tablets +NAs combination therapy 48 weeks

    TQA3605 is taken orally 100mg once daily; Nucleoside (acid) analogues were used once daily for 48 weeks.

    Drug: TQA3605 tablets · Drug: Entecavir dispersible tablets · Drug: Tenofovir disoproxil fumarate tablet · Drug: Tenofovir alafenamide fumarate tablet

  • Active comparator
    200 mg of TQA3605 tablets +NAs combination therapy 48 weeks

    TQA3605 is taken orally 200mg once daily; Nucleoside (acid) analogues were used once daily for 48 weeks.

    Drug: TQA3605 tablets · Drug: Entecavir dispersible tablets · Drug: Tenofovir disoproxil fumarate tablet · Drug: Tenofovir alafenamide fumarate tablet

  • Placebo comparator
    Placebo +Nucleoside (acid) analogs (NAs) combination therapy

    Placebo taken orally once daily, continue for 12 weeks. Placebo was then combined with nucleoside (acid) analogues (once daily) for 36 weeks

    Drug: Placebo · Drug: Entecavir dispersible tablets · Drug: Tenofovir disoproxil fumarate tablet · Drug: Tenofovir alafenamide fumarate tablet

  • Active comparator
    100 mg of TQA3605 tablets +NAs combination therapy

    TQA3605 was taken orally 100mg once a day for 12 weeks. It was then combined with nucleoside (acid) analogues (once daily) for 36 weeks.

    Drug: TQA3605 tablets · Drug: Entecavir dispersible tablets · Drug: Tenofovir disoproxil fumarate tablet · Drug: Tenofovir alafenamide fumarate tablet

  • Active comparator
    200 mg of TQA3605 tablets +NAs combination therapy

    TQA3605 was taken orally 200mg once a day for 12 weeks. It was then combined with nucleoside (acid) analogues (once daily) for 36 weeks.

    Drug: TQA3605 tablets · Drug: Entecavir dispersible tablets · Drug: Tenofovir disoproxil fumarate tablet · Drug: Tenofovir alafenamide fumarate tablet

  • Active comparator
    300 mg of TQA3605 tablets+NAs combination therapy

    TQA3605 was taken orally 300mg once a day for 12 weeks. It was then combined with nucleoside (acid) analogues (once daily) for 36 weeks.

    Drug: TQA3605 tablets · Drug: Entecavir dispersible tablets · Drug: Tenofovir disoproxil fumarate tablet · Drug: Tenofovir alafenamide fumarate tablet

Interventions

06

What researchers measure

Primary outcomes

  1. The incidence of adverse events (AEs)

    The incidence of adverse events (AEs) during treatment

    Time frame: Up to 48 weeks

  2. Severity of adverse events (AEs)

    The severity of adverse events (AEs) during treatment

    Time frame: Up to 48 weeks

  3. Incidence of serious adverse events (SAEs)

    The incidence of serious adverse events (SAEs) during treatment

    Time frame: Up to 48 weeks

  4. Severity of serious adverse events (SAEs)

    The severity of serious adverse events (SAEs) during treatment

    Time frame: Up to 48 weeks

Secondary outcomes

  1. Incidence of abnormal laboratory test values

    The incidence of abnormal laboratory values during treatment, e.g. triglycerides.

    Time frame: Up to 48 weeks

  2. Severity of abnormal laboratory test values

    The severity of abnormal laboratory values during treatment, e.g. triglycerides.

    Time frame: Up to 48 weeks

  3. Deoxyribonucleic acid level of hepatitis B virus

    Changes in hepatitis B virus deoxyribonucleic acid (HBV DNA) levels from baseline

    Time frame: At week 12, week 24, week 36 and week 48 or when subjects withdrawal from the study

  4. Hepatitis B surface antigen

    Changes in serum hepatitis B surface antigen (HBsAg) from baseline

    Time frame: At week 12, week 24, week 36 and week 48 or when subjects withdrawal from the study

  5. Hepatitis B e antigen

    Changes in serum hepatitis B e antigen (HBeAg) from baseline

    Time frame: At week 12, week 24, week 36 and week 48 or when subjects withdrawal from the study

  6. Serologic clearance and/or serologic conversion of HBsAg

    Proportion of subjects with HBsAg serologic clearance and/or serologic conversion

    Time frame: At week 12, week 24, week 36 and week 48 or when subjects withdrawal from the study

  7. Serologic clearance and/or serologic conversion of HBeAg

    Proportion of subjects with HBeAg serologic clearance and/or serologic conversion

    Time frame: At week 12, week 24, week 36 and week 48 or when subjects withdrawal from the study

  8. Virological breakthrough rate

    The proportion of subjects who achieved a virological breakthrough (defined as a confirmed increase of HBV DNA levels \>1.0 log10 IU/ml from the minimum during treatment).

    Time frame: At week 12, week 24, week 36 and week 48 or when subjects withdrawal from the study

  9. Peak time (Tmax)

    Time to reach peak blood concentration after a single dose

    Time frame: pre-dose, 30 minutes, 1 , 2 , 4 , 6 , 12, 24 hours after administration on Day 1; pre-dose on Day 8 and Day 9; pre-dose, 30 minutes, 1, 2, 4, 6, 12, 24 hours after administration on Day 10.

  10. Peak concentration

    The highest plasma drug concentration that can be achieved after medication

    Time frame: pre-dose, 30 minutes, 1 , 2 , 4 , 6 , 12, 24 hours after administration on Day 1; pre-dose on Day 8 and Day 9; pre-dose, 30 minutes, 1, 2, 4, 6, 12, 24 hours after administration on Day 10.

  11. Area under blood concentration-time curve (AUC)

    The amount of drug absorbed into the human circulation after a single dose can be estimated using the area under the blood concentration-time curve

    Time frame: pre-dose, 30 minutes, 1 , 2 , 4 , 6 , 12, 24 hours after administration on Day 1; pre-dose on Day 8 and Day 9; pre-dose, 30 minutes, 1, 2, 4, 6, 12, 24 hours after administration on Day 10.

  12. Apparent volume of distribution (Vd/F)

    When a drug reaches homeostasis in the body, the ratio of the amount of drug in the body to the blood concentration is called the apparent volume of distribution.

    Time frame: pre-dose, 30 minutes, 1 , 2 , 4 , 6 , 12, 24 hours after administration on Day 1; pre-dose on Day 8 and Day 9; pre-dose, 30 minutes, 1, 2, 4, 6, 12, 24 hours after administration on Day 10.

  13. Plasma clearance

    The amount of plasma that the kidneys completely clear in unit time (per minute).

    Time frame: pre-dose, 30 minutes, 1 , 2 , 4 , 6 , 12, 24 hours after administration on Day 1; pre-dose on Day 8 and Day 9; pre-dose, 30 minutes, 1, 2, 4, 6, 12, 24 hours after administration on Day 10.

  14. Elimination half-life

    The time it takes for the plasma concentration to drop by half.

    Time frame: pre-dose, 30 minutes, 1 , 2 , 4 , 6 , 12, 24 hours after administration on Day 1; pre-dose on Day 8 and Day 9; pre-dose, 30 minutes, 1, 2, 4, 6, 12, 24 hours after administration on Day 10.

  15. Steady state peak time

    The time required to reach peak steady-state concentration after administration

    Time frame: pre-dose, 30 minutes, 1 , 2 , 4 , 6 , 12, 24 hours after administration on Day 1; pre-dose on Day 8 and Day 9; pre-dose, 30 minutes, 1, 2, 4, 6, 12, 24 hours after administration on Day 10.

  16. Steady state maximum concentration

    The highest blood concentration that occurs after stabilization

    Time frame: pre-dose, 30 minutes, 1 , 2 , 4 , 6 , 12, 24 hours after administration on Day 1; pre-dose on Day 8 and Day 9; pre-dose, 30 minutes, 1, 2, 4, 6, 12, 24 hours after administration on Day 10.

  17. Steady state minimal concentration

    The lowest blood concentration that occurs after stabilization

    Time frame: pre-dose, 30 minutes, 1 , 2 , 4 , 6 , 12, 24 hours after administration on Day 1; pre-dose on Day 8 and Day 9; pre-dose, 30 minutes, 1, 2, 4, 6, 12, 24 hours after administration on Day 10.

07

Study locations

3 sites
  • The Second Affiliated Hospital of Chongqing Medical University
    Chongqing, Chongqing 400010, China
  • The First Affiliated Hospital of the Chinese People's Liberation Army Army Medical University
    Chongqing, Chongqing 400038, China
  • The First Affiliated Hospital of Xi'an Jiaotong University
    Xi'an, Shannxi 710061, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Dec 2023 (actual). Primary completion is estimated for Dec 2025, 24 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 20, 2023
First posted
Nov 29, 2023
StartActual
Dec 7, 2023
Primary completionEst.
Dec 2025
CompletionEst.
Sep 2026
Last update
Nov 14, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 14, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06150014
Responsible party
Sponsor
First posted
Nov 29, 2023
Start date
Dec 7, 2023
Primary completion
Dec 2025 (estimated)
Completion
Sep 2026 (estimated)
Last update
Nov 14, 2024

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: TQA3605

Start the discussion